5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity.
Antipsychotic treatment can produce supersensitivity to dopamine receptor stimulation. This compromises the efficacy of ongoing treatment and increases the risk of relapse to psychosis upon treatment cessation. Serotonin 5-HT2 receptors modulate dopamine function and thereby influence dopamine-dependent responses. Here we evaluated the hypothesis that 5-HT2 receptors modulate the behavioural expression of antipsychotic-induced dopamine supersensitivity. To this end, we first treated rats with the antipsychotic haloperidol using a clinically relevant treatment regimen. We then assessed the effects of a 5-HT2 receptor antagonist (ritanserin; 0.01 and 0.1mg/kg) and of a 5-HT2A receptor antagonist (MDL100,907; 0.025-0.1mg/kg) on amphetamine-induced psychomotor activity. Antipsychotic-treated rats showed increased amphetamine-induced locomotion relative to antipsychotic-naïve rats, indicating a dopamine supersensitive state. At the highest dose tested (0.1mg/kg for both antagonists), both ritanserin and MDL100,907 suppressed amphetamine-induced locomotion in antipsychotic-treated rats, while having no effect on this behaviour in control rats. In parallel, antipsychotic treatment decreased 5-HT2A receptor density in the prelimbic cortex and nucleus accumbens core and increased 5-HT2A receptor density in the caudate-putamen. Thus, activation of either 5-HT2 receptors or of 5-HT2A receptors selectively is required for the full expression of antipsychotic-induced dopamine supersensitivity. In addition, antipsychotic-induced dopamine supersensitivity enhances the ability of 5-HT2/5-HT2A receptors to modulate dopamine-dependent behaviours. These effects are potentially linked to changes in 5-HT2A receptor density in the prefrontal cortex and the striatum. These observations raise the possibility that blockade of 5-HT2A receptors might overcome some of the behavioural manifestations of antipsychotic-induced dopamine supersensitivity.
Department of Pharmacology, Faculty of Medicine, Université de Montréal, Canada.
Alexandra
A
Charron
Department of Pharmacology, Faculty of Medicine, Université de Montréal, Canada.
Cynthia El
CE
Hage
Department of Neuroscience, Faculty of Medicine, Université de Montréal, Canada.
Alice
A
Servonnet
Department of Pharmacology, Faculty of Medicine, Université de Montréal, Canada; CNS Research Group, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada. Electronic address: Anna.samaha@umontreal.ca.
Anne-Noël
AN
Samaha
D000661:Amphetamine / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D006220:Haloperidol / Q000494:pharmacology; D008124:Locomotion / Q000187:drug effects*; D008297:Male; D011485:Protein Binding / Q000187:drug effects; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D044348:Receptors, Serotonin, 5-HT2 / Q000378:metabolism*; D018490:Serotonin Agents / Q000494:pharmacology; D014316:Tritium / Q000493:pharmacokinetics
D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D044348:Receptors, Serotonin, 5-HT2; D018490:Serotonin Agents; D014316:Tritium; D000661:Amphetamine; D006220:Haloperidol; D004298:Dopamine
5-HT(2) receptors; Amphetamine; Antipsychotic medication; Dopamine supersensitivity; Locomotor activity; Schizophrenia